MCID: OPT003
MIFTS: 50

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 15
Opioid Dependence 74 54 17
Opioid-Related Disorders 71
Opioid Type Dependence 12
Opiate Addiction 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD9CM 34 304.00
MeSH 43 D009293
SNOMED-CT 67 75544000
ICD10 32 F11.2
UMLS 71 C0027412 C0524662

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid dependence, is related to opioid dependence 1 and opioid addiction. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Valproic acid and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Opioid use disorder (OUD) is a pattern of opioid use that causes significant impairment or distress.... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 34.7 OPRM1 ODS1
2 opioid addiction 32.8 OPRM1 OPRK1 OPRD1 DRD2
3 heroin dependence 32.0 SLC6A4 PDYN OPRM1 OPRD1 DRD2 ANKK1
4 morphine dependence 31.1 TH PENK PDYN OPRM1 OPRL1 OPRK1
5 polysubstance abuse 30.4 DRD3 DRD2
6 antisocial personality disorder 30.3 SLC6A4 DRD2 ANKK1
7 phobic disorder 30.2 SLC6A4 POMC DRD2
8 generalized anxiety disorder 30.2 TPH1 SLC6A4 DRD2
9 cocaine abuse 30.2 SLC6A4 OPRK1 NGF DRD3 DRD2
10 mental depression 30.1 TPH1 SLC6A4 POMC DRD3 DRD2 CREB1
11 personality disorder 30.1 TPH1 TH SLC6A4 DRD3 DRD2 ANKK1
12 sexual disorder 30.1 SLC6A4 POMC IGF1 DRD3 DRD2
13 panic disorder 30.1 TPH1 SLC6A4 POMC DRD3 DRD2
14 schizoaffective disorder 30.1 SLC6A4 DRD3 DRD2
15 neonatal abstinence syndrome 30.1 PDYN OPRM1 OPRL1 OPRK1 OPRD1
16 borderline personality disorder 30.0 TPH1 TH SLC6A4 DRD2
17 conduct disorder 30.0 TPH1 SLC6A4 POMC DRD2
18 restless legs syndrome 30.0 TH SLC6A4 POMC DRD3 DRD2
19 alcohol use disorder 29.9 SLC6A4 OPRM1 DRD3 DRD2 CREB1 ANKK1
20 alexithymia 29.9 SLC6A4 DRD2 ANKK1
21 post-traumatic stress disorder 29.9 SLC6A4 POMC FOS DRD2
22 obsessive-compulsive personality disorder 29.8 SLC6A4 DRD3
23 sleep disorder 29.8 TH SLC6A4 POMC IGF1 FOS DRD2
24 somatoform disorder 29.8 TPH1 SLC6A4 OPRM1 OPRL1 NGF
25 eating disorder 29.7 SLC6A4 POMC OPRM1 DRD3 DRD2 ANKK1
26 substance abuse 29.7 SLC6A4 POMC PDYN OPRM1 OPRL1 OPRK1
27 major depressive disorder 29.6 TPH1 SLC6A4 POMC OPRM1 NGF DRD3
28 diarrhea 29.5 TPH1 SLC6A4 POMC OPRM1 OPRK1 OPRD1
29 neuroblastoma 29.5 TH OPRM1 NGF IGF1 FOS CREB1
30 mood disorder 29.5 TPH1 TH SLC6A4 POMC DRD3 DRD2
31 tobacco addiction 29.4 TPH1 SLC6A4 PDYN OPRM1 DRD3 DRD2
32 trigeminal neuralgia 29.3 SLC6A4 OPRM1 OPRL1 OPRK1 OPRD1 NGF
33 psychotic disorder 29.3 TPH1 TH SLC6A4 PDYN OPRM1 DRD3
34 obsessive-compulsive disorder 29.2 TPH1 SLC6A4 POMC PDYN IGF1 DRD3
35 cocaine dependence 29.0 SLC6A4 POMC PDYN OPRM1 OPRK1 OPRD1
36 attention deficit-hyperactivity disorder 29.0 TPH1 TH SLC6A4 OPRM1 NGF FOS
37 constipation 28.9 TPH1 TH SLC6A4 PDYN OPRM1 OPRL1
38 drug dependence 28.8 SLC6A4 POMC PENK PDYN OPRM1 OPRL1
39 bipolar disorder 28.8 TPH1 TH SLC6A4 PDYN NGF IGF1
40 substance dependence 28.7 TPH1 SLC6A4 POMC PDYN OPRM1 OPRL1
41 withdrawal disorder 28.6 POMC PENK PDYN OPRM1 OPRL1 OPRK1
42 anxiety 28.6 TPH1 TH SLC6A4 POMC PDYN OPRM1
43 pain agnosia 28.3 POMC PENK PDYN OPRM1 OPRL1 OPRK1
44 alcohol dependence 28.3 TPH1 TH SLC6A4 POMC PDYN OPRM1
45 opioid abuse 28.2 PENK PDYN OPRM1 OPRL1 OPRK1 OPRD1
46 schizophrenia 27.7 TPH1 TH SLC6A4 POMC PDYN OPRM1
47 migraine with or without aura 1 27.7 TPH1 SLC6A4 POMC PDYN OPRM1 OPRL1
48 wissler-fanconi syndrome 10.5 TPH1 POMC
49 galactorrhea 10.4 IGF1 DRD2
50 tic disorder 10.4 SLC6A4 DRD3 DRD2

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 CREB1 DRD2 DRD3 FOS NGF NPFF
2 homeostasis/metabolism MP:0005376 10.22 CREB1 DRD2 DRD3 FOS IGF1 NGF
3 growth/size/body region MP:0005378 10.18 CREB1 DRD2 DRD3 FOS IGF1 NGF
4 endocrine/exocrine gland MP:0005379 10.14 CREB1 DRD2 FOS IGF1 OPRK1 OPRM1
5 integument MP:0010771 10.1 DRD2 FOS IGF1 NGF OPRD1 OPRK1
6 adipose tissue MP:0005375 10.06 DRD2 DRD3 FOS IGF1 OPRM1 PDYN
7 nervous system MP:0003631 10 CREB1 DRD2 DRD3 FOS IGF1 NGF
8 no phenotypic analysis MP:0003012 9.56 DRD2 NGF OPRD1 OPRM1 PDYN PENK
9 normal MP:0002873 9.36 CREB1 DRD2 FOS IGF1 KPNA3 NGF

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
3
Ribavirin Approved Phase 4 36791-04-5 37542
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Norepinephrine Approved Phase 4 51-41-2 439260
7
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
8
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
9
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
10
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
11
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
12
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
13
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
14
Tapentadol Approved Phase 4 175591-23-8 9838022
15
Menthol Approved Phase 4 2216-51-5 16666
16
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
17
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
18
Cobicistat Approved Phase 4 1004316-88-4
19
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
20
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
21
Nicotine Approved Phase 4 54-11-5 942 89594
22
Methadone Approved Phase 4 76-99-3 4095
23
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
24
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
25
Trichostatin A Experimental Phase 4 58880-19-6
26
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
27 Adrenergic alpha-Agonists Phase 4
28 Adrenergic Agonists Phase 4
29 Sodium Channel Blockers Phase 4
30 Diuretics, Potassium Sparing Phase 4
31 Anesthetics, General Phase 4
32 Anesthetics, Intravenous Phase 4
33 Immunologic Factors Phase 4
34 Interferon-alpha Phase 4
35 Interferon alpha-2 Phase 4
36 Hypnotics and Sedatives Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
39 Desvenlafaxine Succinate Phase 4 386750-22-7
40 Tea Phase 4
41 Ketorolac Tromethamine Phase 4
42 Adrenergic Agents Phase 4
43 Excitatory Amino Acid Antagonists Phase 4
44 Anti-Infective Agents Phase 4
45 Hormones Phase 4
46 Anticonvulsants Phase 4
47 Calcium, Dietary Phase 4
48 calcium channel blockers Phase 4
49 Cytochrome P-450 Enzyme Inhibitors Phase 4
50 Anti-HIV Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 731)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
3 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
5 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
6 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
7 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
8 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
9 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
10 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
11 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
12 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
13 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
14 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
15 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
16 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
17 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
18 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
19 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
20 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
21 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
22 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
23 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
24 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
25 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
26 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial Completed NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
27 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
28 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
29 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
30 An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression Completed NCT02200406 Phase 4 Desvenlafaxine
31 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
32 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
33 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
34 CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
35 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
36 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
37 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
38 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
39 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
40 Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural Completed NCT02721017 Phase 4 Thoracic epidural (ropivicaine, fentanyl)
41 Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair Completed NCT03149887 Phase 4 Liposomal bupivacaine;Placebo
42 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
43 Gabapentin Regimens and Their Effects on Opioid Consumption Completed NCT03334903 Phase 4 Gabapentin
44 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
45 Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone Recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
46 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
47 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
48 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
49 A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
50 The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis Recruiting NCT04033562 Phase 4 Lidocaine patch

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 71 / NDF-RT 50 :


CLONIDINE HCL PWDR
Clonidine Hydrochloride
Levomethadyl
Levomethadyl Acetate Hydrochloride
Methadone
Methadone Hydrochloride
nalmefene
Nalmefene hydrochloride
Naloxone Hydrochloride
Naltrexone
Naltrexone hydrochloride

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

40
Brain, Testes, Liver, Amygdala, Bone, Skin, Cortex

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 3443)
# Title Authors PMID Year
1
Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region. 61 54
20300121 2010
2
Shared mechanisms for opioid tolerance and a transition to chronic pain. 61 54
20357116 2010
3
Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. 61 54
19403243 2009
4
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. 61 54
18424454 2008
5
Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? 54 61
18193922 2008
6
The opioid system in alcohol and drug dependence: family-based association study. 61 54
17503481 2007
7
Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. 54 61
17416470 2007
8
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. 61 54
16583408 2006
9
In-vitro and in-vivo characterization of a buprenorphine delivery system. 54 61
16536895 2006
10
A functional prodynorphin promoter polymorphism and opioid dependence. 54 61
16314761 2005
11
Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. 61 54
15558714 2005
12
A genetic association study of the mu opioid receptor and severe opioid dependence. 54 61
12960749 2003
13
Introducing a new recruitment approach to sample collection for genetic association studies in opioid dependence. 54 61
12648891 2003
14
D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. 61 54
12497624 2003
15
The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. 61 54
11054765 2000
16
The DRD2 gene in psychiatric and neurological disorders and its phenotypes. 54 61
11256581 2000
17
Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. 61 54
10881203 2000
18
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 54 61
9756053 1998
19
Dopamine D3 receptor gene variants and substance abuse in schizophrenia. 54 61
9702743 1998
20
The role of glutamate in physical dependence on opioids. 61 54
9517399 1998
21
Glutamate in opioid dependence. 61 54
9365966 1997
22
Human pharmacology of the opioid neuropeptide dynorphin A(1-13). 54 61
9190848 1997
23
Stigmatization of opioid addiction based on prescription, sex and age. 61
32447236 2020
24
Continuation of opioid replacement program delivery in the aftermath of cyclones in Queensland, Australia: A qualitative exploration of the perspectives of pharmacists and opioid replacement therapy staff. 61
31753692 2020
25
Prescription opioid overdose and adverse effect hospitalisations among injured workers in eight states (2010-2014). 61
32276968 2020
26
Morphine-element interactions - The influence of selected chemical elements on neural pathways associated with addiction. 61
32179426 2020
27
Predicting prolonged opioid prescriptions in opioid-naïve lumbar spine surgery patients. 61
31901553 2020
28
Care Among Migraine Patients in a Commercially Insured Population. 61
32062840 2020
29
Neurocognitive functions in patients on buprenorphine maintenance for opioid dependence: A comparative study with three matched control groups. 61
32526693 2020
30
Predictors of long-term opioid dependence in transforaminal lumbar interbody fusion with a focus on pre-operative opioid usage. 61
32095906 2020
31
Genetic Variants May Play Role in Opioid Dependence. 61
32453508 2020
32
Antenatal Admissions Among Women with Opioid-Affected and Non-Opioid-Affected Deliveries. 61
32557132 2020
33
Plastic Surgery Patient Expectations for Postoperative Opioid Prescriptions. 61
32039997 2020
34
The Effect of the IPACK Block on Pain After Primary TKA: A Double-Blinded, Prospective, Randomized Trial. 61
32005622 2020
35
Receipt of multiple outpatient opioid prescriptions is associated with increased risk of adverse outcomes in youth: opioid prescribing trends, individual characteristics, and outcomes from 2005 to 2016. 61
31977934 2020
36
Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A Genome-Wide Association Study. 61
32492095 2020
37
Against Repurposing Methadone for Glioblastoma Therapy. 61
32560384 2020
38
Managing long-term high-dose prescription opioids in patients with non-cancer pain: The potential role of sublingual buprenorphine. 61
32464722 2020
39
Finding the Hidden Risk Profiles of the United States Opioid Epidemic: Using a Person-Centered Approach on a National Dataset of Noninstitutionalized Adults Reporting Opioid Misuse. 61
32560342 2020
40
Physical Therapy for Chronic Pain Mitigation and Opioid Use Reduction Among People Living with Human Immunodeficiency Virus in Atlanta, GA: A Descriptive Case Series. 61
32390457 2020
41
Economic burden and clinical impact of preoperative opioid dependence for patients undergoing lower extremity bypass surgery. 61
31495675 2020
42
Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study. 61
31631215 2020
43
Opioid-Related Emergency Department Encounters: Patient, Encounter, and Community Characteristics Associated With Repeated Encounters. 61
31983498 2020
44
Extinction as the behavioral mechanism of the naltrexone-extended release for opioid dependence: could there be an alternative explanation? 61
32358829 2020
45
Hab-o Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial. 61
32109133 2020
46
Exposure to Medicines in the Family Medicine Cabinet: Is It a Harbinger of Later Opioid Dependence? 61
32394779 2020
47
A physician-pharmacist collaborative care model to prevent opioid misuse. 61
32315401 2020
48
Estimating the prevalence of problem drug use from drug-related mortality data. 61
32392631 2020
49
Breast Reconstruction Does Not Increase the Incidence of Postmastectomy Pain Syndrome: Results of a Meta-Analysis. 61
31800549 2020
50
Managing acute pain in HIV+/AIDS patients: knowledge and practice trends among emergency physicians of major tertiary care centers of a developing country. 61
32456673 2020

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 POMC PENK PDYN OPRM1 OPRL1 OPRK1
2
Show member pathways
13.39 POMC PENK PDYN OPRM1 OPRL1 OPRK1
3
Show member pathways
12.59 TH FOS DRD3 DRD2 CREB1
4
Show member pathways
12.47 POMC OPRM1 IGF1 FOS CREB1
5 12.38 TPH1 TH POMC OPRM1 NGF CREB1
6 12.15 POMC FOS DRD2 CREB1
7 11.93 TPH1 TH SLC6A4 NGF CREB1
8 11.79 POMC OPRM1 OPRD1 FOS
9
Show member pathways
11.75 TH DRD3 DRD2
10
Show member pathways
11.73 TH PDYN FOS DRD2 CREB1
11 11.7 POMC FOS CREB1
12 11.64 POMC FOS CREB1
13 11.61 TH NGF IGF1
15 11.41 TH FOS CREB1
16
Show member pathways
10.82 TH SLC6A4 DRD3 DRD2
17 10.56 TH POMC DRD2 ANKK1

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 10.02 SLC6A4 OPRM1 OPRL1 OPRK1 OPRD1 DRD3
2 axon GO:0030424 9.88 TH PENK OPRM1 NGF DRD2 CREB1
3 dendrite GO:0030425 9.86 TH PENK PDYN OPRM1 OPRK1 NPFF
4 perikaryon GO:0043204 9.8 TH PENK OPRM1 OPRK1 NPFF DRD2
5 integral component of postsynaptic membrane GO:0099055 9.67 SLC6A4 OPRM1 OPRK1 DRD2
6 neuron projection GO:0043005 9.56 TPH1 TH SLC6A4 OPRM1 OPRL1 OPRK1
7 integral component of presynaptic membrane GO:0099056 9.55 SLC6A4 OPRM1 OPRK1 OPRD1 DRD2
8 dopaminergic synapse GO:0098691 9.46 DRD3 DRD2
9 spine apparatus GO:0097444 9.43 OPRM1 OPRD1
10 axon terminus GO:0043679 9.1 PENK PDYN OPRK1 OPRD1 NPFF DRD2

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 POMC PENK OPRM1 OPRL1 OPRK1 OPRD1
2 G protein-coupled receptor signaling pathway GO:0007186 10.18 POMC PENK PDYN OPRM1 OPRL1 OPRK1
3 cytokine-mediated signaling pathway GO:0019221 10.03 POMC OPRM1 OPRD1 FOS
4 chemical synaptic transmission GO:0007268 10.01 PENK PDYN OPRK1 NPFF
5 response to drug GO:0042493 10 TH SLC6A4 NPFF FOS DRD3 DRD2
6 response to lipopolysaccharide GO:0032496 9.99 TH PENK OPRM1 FOS
7 response to hypoxia GO:0001666 9.96 TH SLC6A4 PENK DRD2 CREB1
8 response to estradiol GO:0032355 9.94 TH SLC6A4 PENK OPRL1
9 memory GO:0007613 9.91 TH SLC6A4 NGF CREB1
10 response to ethanol GO:0045471 9.91 TH PENK OPRM1 OPRK1 DRD3 DRD2
11 circadian rhythm GO:0007623 9.89 TPH1 SLC6A4 CREB1
12 response to toxic substance GO:0009636 9.89 SLC6A4 PENK FOS DRD3 DRD2
13 cellular response to growth factor stimulus GO:0071363 9.88 TH OPRD1 CREB1
14 excitatory postsynaptic potential GO:0060079 9.87 OPRM1 NPFF DRD2
15 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.87 OPRM1 OPRK1 OPRD1
16 social behavior GO:0035176 9.86 TH SLC6A4 DRD3
17 visual learning GO:0008542 9.85 DRD3 DRD2 CREB1
18 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.85 OPRM1 OPRL1 OPRK1 OPRD1
19 locomotory behavior GO:0007626 9.85 TH PENK OPRM1 OPRK1 DRD3 DRD2
20 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.84 OPRL1 DRD3 DRD2
21 response to radiation GO:0009314 9.84 PENK OPRM1 OPRK1
22 sensory perception of pain GO:0019233 9.84 PENK OPRM1 OPRL1 OPRK1
23 response to amphetamine GO:0001975 9.83 TH DRD3 DRD2
24 response to cocaine GO:0042220 9.83 OPRM1 OPRK1 DRD3 DRD2
25 negative regulation of blood pressure GO:0045776 9.81 OPRL1 DRD3 DRD2
26 response to light stimulus GO:0009416 9.81 TH FOS DRD2
27 response to nicotine GO:0035094 9.81 TH PENK DRD2 CREB1
28 response to immobilization stress GO:0035902 9.79 TPH1 TH FOS
29 behavioral response to cocaine GO:0048148 9.77 OPRK1 DRD3 DRD2
30 synaptic transmission, dopaminergic GO:0001963 9.77 TH DRD3 DRD2
31 estrous cycle GO:0044849 9.76 OPRM1 OPRL1 OPRK1
32 negative regulation of voltage-gated calcium channel activity GO:1901386 9.75 OPRL1 DRD3 DRD2
33 behavioral response to ethanol GO:0048149 9.74 OPRM1 DRD3 DRD2
34 response to growth factor GO:0070848 9.73 TH OPRM1
35 prepulse inhibition GO:0060134 9.73 DRD3 DRD2
36 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.73 DRD3 DRD2
37 dopamine metabolic process GO:0042417 9.73 DRD3 DRD2
38 behavior GO:0007610 9.73 OPRL1 OPRK1
39 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.72 DRD3 DRD2
40 neurotransmitter biosynthetic process GO:0042136 9.72 TH SLC6A4
41 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
42 positive regulation of urine volume GO:0035810 9.72 OPRL1 DRD2
43 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
44 regulation of sensory perception of pain GO:0051930 9.72 OPRM1 OPRL1 OPRK1 OPRD1 NPFF
45 regulation of potassium ion transport GO:0043266 9.71 DRD3 DRD2
46 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.71 OPRM1 DRD3
47 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD3 DRD2
48 opioid receptor signaling pathway GO:0038003 9.71 OPRM1 OPRL1 OPRK1 OPRD1
49 aromatic amino acid family metabolic process GO:0009072 9.7 TPH1 TH
50 hyaloid vascular plexus regression GO:1990384 9.7 TH DRD2

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.97 OPRM1 OPRL1 OPRK1 OPRD1 DRD3 DRD2
2 peptide binding GO:0042277 9.56 OPRM1 OPRL1 OPRK1 OPRD1
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD3 DRD2
4 receptor serine/threonine kinase binding GO:0033612 9.46 OPRK1 OPRD1
5 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD3 DRD2
6 opioid receptor binding GO:0031628 9.4 PENK PDYN
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH1 TH
8 dopamine binding GO:0035240 9.33 TH DRD3 DRD2
9 opioid peptide activity GO:0001515 9.32 PENK PDYN
10 neuropeptide binding GO:0042923 9.26 OPRM1 OPRL1 OPRK1 OPRD1
11 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....